Anatara Lifesciences Ltd · ASX:ANR
Anatara Lifesciences — Finance News Network CEO Conference and Gold Coast Investment Showcase 2016
21 slides from Anatara Lifesciences's conference presentation, Jun 20, 2016
Slide 1: ASX Release: Anatara Investor Presentation
ASX Release Anatara Investor Presentation For personal use only Key points: Anatara to present at Finance News Network CEO Conference (Sydney) and Gold Coast Investment Showcase this week Updated investor presentation attached to this release Anatara has a natural alternative to the widespread
Slide 2: Contact and About Anatara Lifesciences
For more information please contact: Investor and Media inquiries For personal use only Dr Mel Bridges Chairman, Anatara Lifesciences +61 (0) 413 051 600 melbridges@parmacorp.com Media: Jane Lowe IR department +61 (0) 411 117 774 About Anatara Lifesciences Anatara Lifesciences is developing therapeu
Slide 3: Natural Alternative to Antibiotics
For personal use only Natural Alternative to Antibiotics June 2016
Slide 4: Disclaimer
Disclaimer For personal use only The information in this presentation does not constitute personal investment advice. The presentation is not intended to be comprehensive or provide all information required by investors to make an informed decision on any investment in Anatara Lifesciences Ltd, ACN
Slide 5: Key Financial Details
Key Financial Details For personal use only ASX Code ANR Share Price1 $1.20 Market Cap $59 million Ordinary Shares2 49,288,246 Raised at IPO (October 2014) $7 million Placement and SPP (July 2015) $9 million Current Cash1 $13.8 million 1. As at 31 May 2016 2. 13,036,095 shares held by directors, oth
Slide 6: Share Price Chart
ASX:ANR Share Price Chart For personal use only 4
Slide 7: Detach: Oral therapeutics for gastrointestinal disease
Oral therapeutics for gastrointestinal disease in livestock and humans For personal use only Detach™ • Natural, non-antibiotic therapeutic that prevents and treats gastro diseases including diarrhoea • Meets the need to reduce antibiotics in animal production • Unlike antibiotics, Detach™ will not c
Slide 8: Need to combat anti-microbial resistance
Need to combat anti-microbial resistance For personal use only • Anti-microbial resistance is a worldwide threat to public health • Tens of thousands of people die every year because of antibiotic resistant bacteria – so called “Super Bugs” (USA CDC, WHO) • Antibiotic resistance is driven by antibio
Slide 9: Lead Indication – Pigs
Lead Indication – Pigs Diarrhoea affects hundreds of millions of piglets born each year For personal use only 7
Slide 10: Market Opportunity is clear
Market Opportunity is clear • Growing awareness of urgent need to combat anti-microbial resistance For personal use only • Demand for non-antibiotic treatments will rise as authorities act to restrict/ban use of antibiotics in farm animals • Global animal antibiotic market valued at ~ $4.63 billion
Slide 11: Consumer Pressure – Food Quality & Food Safety
Consumer Pressure - Food Quality & Food Safety For personal use only • McDonald's will stop buying chicken reared on antibiotics used in humans within two years (March 2015). • McDonald's is the largest restaurant chain in the world — this move had a major impact on other retailers and will now affe
Slide 12: Consumer Pressure
For personal use only 10 Consumer Pressure
Slide 13: Anatara – A Solution
Anatara – A Solution For personal use only • Detach™ is an orally administered non- antibiotic anti-infective • Proven efficacy – evidence-based therapeutic claims • Proven safety - active ingredient is a natural plant based product • Broad acting against a range of causes of diarrhoea • Stable - do
Slide 14: Detach Mode of action
DetachTM Mode of action DetachTM does not target the pathogen For personal use only DetachTM acts on the underlying cause of diarrhoea Anti‐inflammatory opportunities 1. Chandler and Mynott. 1998. Gut 43:196-202. 2. Mynott, et al., Gut 38:28-32. 3. Mynott, et al. 1997. Gastroenterol. 113:175-184. 4.
Slide 15: Detach: Poised for swift market entry
Detach™ Poised for swift market entry For personal use only • Launch planned in Australia for 2017 • Has a clear path to market • Proven efficacy (therapeutic claims) Current 50 kg scale • Proven safety - active ingredient is GRAS (≈500,000 doses) (generally recognised as safe) • Manufacturing compl
Slide 16: Exclusive Option to license Detach with Zoetis
Exclusive Option to license Detach™ for worldwide commercialisation with Zoetis For personal use only • Aggressive program for evaluation of Detach™ in multiple livestock species • Zoetis will fund cost of validation trials • Upfront and subsequent cash payments • Further strengthens Anatara Balance
Slide 17: What Next? A Pipeline in a Product
What Next? Anatara - A Pipeline in a Product For personal use only Other Detach™ presentations: – Livestock in-feed – Livestock in-water Potential product extensions for the core components of Detach™ Partnering Opportunities for: – Companion animals (cats & dogs – eg. atopic dermatitis) – Over-the-
Slide 18: Human Applications
For personal use only Human Applications “There are 4 billion episodes of diarrhoea in the world annually. Diarrhoea is the second cause of death in children under 5 years, and leading cause of malnutrition.” 16
Slide 19: Human Applications
Human Applications • No product available that prevents all causes of gastrointestinal diseases For personal use only • Diversity of diarrhoea poses a difficulty for drug developers Gastro Related Disorders/Diseases • Inflammatory bowel disease (1.4 million in USA, 2.3 million in EU & Australia) • I
Slide 20: Anatara Investment Overview
Anatara Investment Overview For personal use only • Experienced Board and management team with proven track record • Lead product, DetachTM has a clear route to market: - Commercially validated and proven efficacy - Development strategy de-risked and revenues within 2 years • Well funded – sufficien
Slide 21: Thank you
For personal use only Thank you “With the world’s meat production needs set to rise 100% by 2050, it is important we act now to develop non-antibiotic treatment options.” Dr Mel Bridges, Chairman – Anatara Lifesciences Mel Bridges, Chairman and Co-founder melbridges@parmacorp.com +61 413 051 600 19